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ABSTRACT 
1, 4-dihydropyridine calcium channels blockers (DHPs) are the most commonly used antihypertensive drugs. Unfortunately, these compounds have 
a significant degradability to light. The oxidation to the pyridine derivative represents the first, and in many cases the only, step of the degradation 
mechanism. The photodegradation process causes the complete loss of pharmacological activity and may trigger the formation of single and 
superoxide oxygen species, potentially responsible for phototoxic reactions. Several analytical techniques have been proposed for DHP 
determination in the presence of their photoproducts. Nowadays, DHPs are all marketed in solid formulations, especially tablets, because 
photodegradation is particularly fast in solution. Various approaches aimed to protect molecular integrity and therapeutic activity of these drugs 
from the effects of light are currently studied. This review covers the studies over the last years about photodegradation of the DHPs and the 
approaches to obtain photostable formulations of these drugs. 
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Calcium channel blockers are drugs known and used in clinical 
practice for many years. The first drug of this class was verapamil, 
introduced in therapy in the 60s as a selective coronary vasodilator 
and become in 80-90 y the best-selling antihypertensive agent. 
Another important step was reached in 1969 with the discovery of 
nifedipine, the lead of the 1,4-dihydropyridine drugs (DHPs), 
approved for use in the United States in 1981. Nowadays, the 
calcium channel blockers are the most prescribed drugs in 
hypertensive patients [1]. Chemically, they are classified into two 
main categories, DHP derivatives and non-DHP derivatives, 
comprising verapamil and diltiazem congeners [2]. 
These drugs act on voltage-operated channels (VOC) by binding to the 
channel during the inactivated state, thereby prolonging the duration 
of this state and, therefore, preventing the entry of calcium into the cell 
[3]. The consequence is the impediment to the smooth muscles to 
contract, producing a final relaxation of muscle peripheral resistance 
and hence hypotension [4]. The effects are expressed on smooth and 
cardiac muscle and even beyond the blood-brain barrier. In fact, some 
DHPs work better on certain types of vessels, for example on the 
coronary arteries or the cerebral vessels [5]. The striated muscles are 
free from these effects because the mechanism is a function of the 
calcium already present within the cells.  
Several congeners have been synthesized and marketed after 
nifedipine, which have improved and expanded the therapeutic 
effects and at the same time sought to limit side effects and prolong 
the half-life. Currently, calcium antagonists used as antihypertensive 
agents are almost exclusively DHP compounds, while non-DHP drugs 
are mainly used as antiarrhythmics [5-7].  
DHPs can be classified in three generations:  
• A first-generation comprising above all nifedipine and 
nicardipine;  
• A second-generation including felodipine, nimodipine, 
nisoldipine, nitrendipine, isradipine;  
• A third-generation comprising amlodipine, barnidipine, 
lacidipine, lercanidipine, manidipine. 
In particular, the DHPs belonging to the third-generation are 
characterized by a longer half-life, due to a higher lipophilicity and 
receptor affinity. At the same time, they present reduction of side 
effects, as headache, excessive hypotension, edema and tachycardia.  
Studies on photodegradation of drugs, and in particular DHP 
antihypertensive, have begun for many years but the number of 
publications on this topic has increased over time, demonstrating a 
great deal of interest by a good number of researchers. This review 
focuses on the results published over the last twenty years. In some 
cases, the reported references are of previous years but have been of 
great importance to the subject or are the only ones published for a 
particular drug. 
Table 1 lists the main DHPs used in therapy. 
 
Table 1: Chemical structures of dihydropyridine drugs 
 
   
Amlodipine Aranidipine Azelnidipine Barnidipine 
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Photochemistry of 1, 4-dihydropyridines 
The DHP drugs exhibit high sensitivity to light, undergoing a photo 
degradation process consisting, in most of the cases, in the oxidation 
of the dihydropyridine ring to pyridine derivative, as shown in fig. 1 
[8, 9].  
 
 
Fig. 1: Photodegradation of DHP to pyridine derivative 
 
In a limited number of DHPs, a more complex degradation has been 
demonstrated with the formation of secondary photoproducts. 
These molecular changes lead to loss of therapeutic effect or in some 
cases to toxic effects. Because of their high photo-lability in solution, 
almost all DHPs are dispensed in solid formulations, usually tablets, 
where the stability is significantly high [10, 11]. Different analytical 
approaches have been proposed for the determination of DHPs in 
the presence of their photoproducts. The principal studies on the 
degradation mechanism common to most DHP drugs are described 
in this section. The analytical methods specific to each drug will be 
described in a later chapter. 
The photochemistry of a series of DHPs bearing a substituent on the 
phenyl ring, as 4-(chlorophenyl) and 4-(4’-nitrophenyl) derivatives, 
was studied. All of these compounds underwent aromatization to 
give the pyridine by-products, devoid of any therapeutic effect. This 
process is initiated by proton transfer, probably to the solvent, from 
the excited singlet and is scarcely affected by the molecular oxygen. 
The presence of a nitro-group on the phenyl ring increases the 
process of aromatization because the delocalization of the negative 
charge is favorite, facilitating ionization and deprotonation [12]. 
Simultaneous determination of several DHPs and respective 
photoproducts was defined through a classical least squares (CLS) 
model built on the UV spectral data. A procedure for selecting the 
more useful wavelength ranges to use in calibration was also 
proposed. The good accuracy of the procedure was demonstrated by 
the recovery values over 97% [13]. Photodegradation kinetics of 
nitrendipine and felodipine, exposed to UV and daylight in methanol 
solutions, was determined by processing the UV data in a self-
modeling multivariate curve resolution (MCR) method based on 
iterative target transformation and Kubista method. Concentration 
profiles and spectra of drugs and photoproducts were determined. 
The reaction was proved to be zero-order at the beginning of 
lighting, changing to a first-order when the concentration of 
photoproducts increased [14]. 
Light sensitivity of eleven DHPs was correlated against a series of 
molecular descriptors through a quantitative structure-property 
relationships (QSPR) model. The photodegradation rates, calculated 
from the spectral data collected throughout stressing photo 
degradation experiments, were combined with the values of the 
molecular descriptors by Partial Least Squares (PLS) analysis. The 
variables fitting the PLS model were selected and the resulting QSPR 
model was validated. The model was applied to other DHPs, showing 
good agreement between predicted and measured photodegradation 
rates [15]. Photodegradation of fifteen newly synthesized DHPs was 
monitored by spectrophotometry and the data processed by MCR 
analysis. This multivariate technique allowed to estimate the spectra 
and the concentration of the components involved in the 
degradation process. A single photoproduct was estimated from 
degradation of both DHPs, due to the aromatization of the pyridine 
ring. Traces of a second photoproduct were detected in twelve DHPs 
and a third photoproduct was verified only in one case. High stability 
was demonstrated when the fluorine group was in the position R1 of 
the phenyl ring or simultaneously present in R1 and R2 positions. In 
contrast, the presence of chlorine in R1 or R2
Photodegradation testing 
 strongly increased the 
degradation process [16]. In a second paper of the same Authors, six 
new condensed DHPs were synthesized by microwave irradiation 
method and submitted to forced photodegradation experiments. The 
formation of the oxidized pyridine derivative was observed for all 
the studied DHPs, except for one compound, which showed a very 
fast degradation and the formation of a second photoproduct [17].  
Research on drug photodegradation has considerably increased 
after 80s. Nowadays, the studies in this field have become an 
important issue in pharmaceutical research and a lot of papers, 
reviews or books on photo-labile drugs and their formulations 
continue to be published. The most important and studied effects 
from photodegradation of the drug are the formation of inactive or 
toxic products or photoallergic and photomutagenic effects [18-21]. 
In the last few years, chemical mechanisms and photodegradation 
kinetics have been described for a high number of drugs. Some 
reviews or books, published in the first decade of the twentieth 
century, deal very deeply with photolabile drugs and their 
formulation problems [22-24]. 
At present, it is compulsory for the pharmaceutical industry to 
conduct photoreactivity studies on drugs in formulation and 
packaging processes [25]. An overall stress testing for the new drugs 
is detailed in the rules ICH (International Conference on 
Harmonization), adopted since 1997 by the European Community, 
the United States and Japan. In particular, second part Q1B 
"Photostability testing of new drug substances and products" is an 
integral part of the overall stress testing [26]. The tests need to be 
performed on the pure drug substance and on the drug outside of 
the immediate pack. If necessary, other tests should be performed 
on both immediate and marketing packs. ICH rules include the 
optional use of two different light sources:  
1) Any light source able to produce an output similar to the 
D65/ID65 emission standard. D65 is the standard for outdoor 
daylight and ID65 is the equivalent indoor indirect daylight 
standard.  
2) A cool white fluorescent light source combined with a near 
ultraviolet lamp.  
During the stress test, the temperature must be monitored to 
minimize any change caused by the light source. Photostability 
testing involves a first forced degradation test to evaluate the global 
photosensitivity of the drug, used for analytical aims, and a 
confirmatory testing to establish the information useful for drug 
handling, packaging and labeling. The use of solar radiation is not 
recommended because of its dependence on the geographical 
position and climate [25]. The ICH rules have been subject to 
criticism by some researchers. In 2010, Baertschi et al. discussed the 
application of ICH Guideline to conduct drug stability tests [27]. 
After that, other papers from the same Authors were published, 
detailing the conduction of the tests on various pharmaceutical 
forms [28, 29]. 
Photodegradation studies on dihydropyridine drugs 
This chapter reports the main studies on photodegradation of a large 
number of DHPs. For some structures listed in table 1, no specific 
work on their photodegradation process has been published. 
Amlodipine 
Amlodipine is one of the most used DHPs to treat hypertension and 
prevent angina chest pain. The photo-lability of this drug has been 
well documented and several analytical methods have been 
proposed. A mechanistic study on the photodegradation of 
amlodipine besylate was carried out in water and in organic 
solvents. Irradiation caused aromatization with the formation of the 
pyridine by-product through an oxygen-independent process. The 
photo-lability of this drug was justified by the high absorption in the 
UV-A range [30]. A derivative spectrophotometric method was 
defined for the simultaneous determination of amlodipine and its 
pyridine photoproduct by correlating the concentrations of the 
analytes with the specific spectral signals in the third-order UV 
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derivative spectrum. Recovery values from 95 to 99% and limit of 
quantitation (LOQ) of 1% for the by-product demonstrated the 
satisfactory validity of this method [31].  
Since UV light is often used in water disinfection, amlodipine and 
other calcium antagonists (diltiazem and verapamil) were 
monitored in water under UV irradiation at 254 nm. The 
photoproducts were separated by solid phase extraction (SPE) and 
identified to assess the potential ecological risks [32]. Still for 
environmental risk assessment, amlodipine photo degradation 
was studied under solar radiation and xenon lamp. Sixteen 
photoproducts were identified through chromatography with 
mass detector UHPLC-QTOF-MS. Some of them are secondary 
products originated in turn from the first pyridine derivative, 
which was the only photoproduct resulting in environmental 
waters and in sewage [33]. 
An RP-HPLC isocratic method was applied to amlodipine besylate 
solutions subjected to photodegradation as well as to acid and 
alkaline hydrolysis and chemical oxidation. After 14 d in an 
irradiation camera, the drug solution showed a degradation of 
32.2% [34]. Photo stability of amlodipine was studied also in solid 
formulations. The tablets were exposed to light from a D65 lamp, 
according to ICH-Q1B rules, and photodegradation was monitored 
by HPLC using a reversed phase column with UV detection. Although 
much more slowly than the reaction in solution, photochemical 
reactions confirmed the aromatization of the dihydropyridine ring 
and the conversion of the nitro group to nitroso group [11].  
Aranidipine 
Aranidipine has good antihypertensive activity but its preferential 
use is in the therapy of angina pectoris [35]. The drug has shown 
photo-lability but only one study on the toxicity of the main photo 
degradation product in mice has been published. No toxic signs were 
observed during the observation period following administration of 
the photoproduct [36]. 
Azelnidipine 
Azelnidipine has been approved in Japan for the treatment of 
hypertension, with selectivity for L-type calcium channels. The 
antihypertensive efficacy of azelnidipine is similar to that of 
amlodipine or nitrendipine. It is usually well tolerated and its use is 
not associated with reflex tachycardia [37]. An RP-HPLC procedure 
was developed for the simultaneous determination of azelnidipine 
and olmesartan, as a stability-indicating method under forced 
degradation conditions (photolysis as well as hydrolysis and 
oxidation). Drug photostability was tested by exposing the drug in 
solid form to direct sunlight on summer days. Azelnidipine showed 
extensive degradation under all conditions but good stability when 
exposed to humidity [38]. As noted above, testing the 
photosensitivity of a drug under direct sunlight is of little value since 
natural conditions do not have standardized and repeatable 
features. However, this work is the only one dealing with the 
photodegradation of this drug. 
Barnidipine 
Barnidipine is a long-term DHP and its antihypertensive action is 
related to the reduction of peripheral vascular resistance secondary 
to its vasodilatory action [39]. An accurate study on the behavior of 
barnidipine when exposed to natural and stressing light irradiation 
was conducted, showing different photodegradation processes 
under these two light sources [40]. Kinetics of the process was 
determined by HPLC and spectrophotometry. Exposure of the drug 
to sunlight caused oxidation to give the pyridine derivative as the 
main photoproduct. In contrast, under stressing irradiation, a 
complex degradation pathway caused the formation of numerous 
by-products (fig. 2). 
 
 
Fig. 2: Scheme of photodegradation mechanism of barnidipine 
 
In another papers, four barnidipine impurities were detected by 
HPLC, then identified, synthesized, and subsequently characterized 
by their respective MS, 1H-NMR and 13
Benidipine 
C-NMR spectral data [41, 42]. 
Determination of benidipine hydrochloride in pure form and 
pharmaceuticals was defined by a first-order derivative 
spectrophotometric method. Forced degradation studies were 
conducted by exposing the drug to stress conditions. Also for this 
drug, degradation leads to oxidation of the molecule with 
aromatization of the dihydropyridine ring. The procedure was 
validated according to the ICH guidelines with respect to accuracy, 
precision, linearity, limit of detection, LOQ [43]. 
Cilnidipine 
A specific and highly sensitive stability indicating RP-HPLC method 
with photodiode array detection was developed for the estimation of 
cilnidipine in bulk and pharmaceutical formulations. Reliability and 
analytical performance of the method were validated for LOQ, 
linearity, precision, accuracy and specificity.  
The drug was subdued to forced degradation under photolytic, 
acidic, basic, oxidative and thermal conditions and all degradation 
products were resolved. Photo degradation studies were conducted 
by exposing the drug to UV radiation. Three photoproducts were 
detected, but unidentified, and a degradation of 10.45% was 
calculated after 24 h [44]. 
Ragno et al. 




MS and NMR techniques were used for the structural characterization 
of eleven potential impurities of clevidipine butyrate, including 
process-related compounds and degradation products. An RP-HPLC 
method was developed to separate and quantify the impurities. Under 
light irradiation, the major degradation product was confirmed to be 
the pyridine derivative [45]. 
Felodipine 
A stability indicating RP-HPLC method was developed for the assay 
of felodipine as a bulk drug and in pharmaceuticals. Separation of 
the drug peak from the peaks of the photodegradation products was 
satisfactory. No interference was relieved from the tablet excipients 
[46]. A different photo-physical and photochemical behavior was 
found between felodipine and nimodipine. Felodipine showed a 
major reactivity in its ground state towards electrophilic transient 
species like singlet oxygen. In contrast, nimodipine showed higher 
reactivity and photo-lability in the excited state. Felodipine is less 
photo-labile than nimodipine probably because of a lowered 
stability of the zwitterion radical involved in the photodegradation 
reaction. These results could be very useful to study the 
photoallergic and phototoxic effects from these drugs [47]. 
Flordipine 
A comparative study was conducted on flordipine tablets exposed 
directly to light or covered with amber vinyl sheeting. The tablets 
were exposed to accelerated light conditions, under 150 foot candles 
of fluorescent light. The data demonstrated that the amber colored 
vinyl sheeting had an excellent protective effect on the discoloration 
of the tablets [48].  
Furnidipine 
Photodecomposition of furnidipine was studied by UV-vis 
spectrophotometry, HPLC and voltammetry under artificial daylight, 
UV light and room daylight. The daylight photoproduct was isolated 
and identified by NMR and IR as the nitrosophenyl-pyridine 
derivate. Quantitative kinetic data for the UV photodecomposition of 
furnidipine was not obtained due to a rate of degradation under 1 
min. However, the nitrophenyl-pyridine by-product was identified 
as the main photoproduct [49]. 
Isradipine 
The photochemical decomposition of isradipine was evaluated by 
calculating the photodegradation rate constant, the half-life period 
and the time of 10% degradation. The photodegradation process 
was assessed by UV spectrophotometry, HPLC and HPTLC 
chromatography. The formation of inclusion complexes of isradipine 
with M-βCD was proved to increase twice the photostability of the 
drug [50]. 
Lacidipine 
Photostability of lacidipine was studied in solutions exposed to UV-A 
radiations. Separation among the drug and its photoproducts was 
done by HPLC. The main photodegradation products were isolated 
and characterized [10]. The photodegradation mechanism proposed 
in this work (fig. 3) differs from those usually described for the other 
DHPs and consisted in a first isomerization followed by a cyclization 
involving both benzene and pyridine rings. 
Another stability-indicating HPLC method was developed for the 
determination of lacidipine in the presence of its degradation 
products and applied to the analysis of the drug in bulk and in 
commercial tablets. The procedure was used to investigate the 
kinetics of photo-induced, alkaline and acidic degradation, 
confirming an apparent first-order rate constant [51]. The 
simultaneous determination of lacidipine and its main photoproduct, 
resulting from the cyclization reaction above described, was 
performed by applying the fractional wavelet transform (FWT) 
technique to the absorption spectra of the compounds. The resulting 
FWT spectra were processed by continuous wavelet transform 
(CWT) and multilinear regression calibration (MLRC).  
The method was simple, rapid and not requiring any chemical 
separation [52]. The same binary mixture was analyzed by means of 
the "zero-crossing" technique in derivative spectrophotometry and 
the results compared with those from multivariate procedures. The 
chemometric methods demonstrated a better prediction ability, 
showing recovery of 101-103% and 96-98% for drug and 
degradation product, respectively. In contrast, the derivative 
spectrophotometric method suffered from the use of the signals 
along the slopes of the spectral curve, giving lower accurate and 
precise results [53]. 
 
 
Fig. 3: Cis-isomerization and cyclization of lacidipine 
 
Lercanidipine 
The photo degradation process of lercanidipine was investigated by 
UV spectrophotometry and liquid chromatography. The drug and its 
main photoproducts were separated by HPLC and characterized by 
MS detection, using an electrospray ionization source (ESI) and an 
ion trap analyzer. The pathway of the process included a first 
aromatization of the dihydropyridine ring followed by the formation 
of nitroso-derivatives and N-dealkylation in the side chain [54]. 
Manidipine 
Determination of manidipine and its pyridine derivative was 
developed by applying a CLS regression method on the UV spectral 
data. This procedure was optimized by an appropriate selection of 
the most useful wavelength ranges. Quantification limit for the 
photoproduct concentration was estimated as 1.0% [55]. Manidipine 
degradation under forced conditions, according to the ICH 
guidelines, was studied also using an HPLC method with UV and MS 
detection. A comprehensive degradation pathway and the identity of 
the major products were defined. The degradation kinetics could be 
best described as zero-order process [56]. 
Nicardipine 
The simultaneous determination of nicardipine and its pyridine 
photoproduct was proposed by using a fourth-order derivative 
spectrophotometric method. The analytes concentrations were 
correlated with specific spectral measurements through equations 
obtained by simple and multiple regression analysis [57]. The 
photodegradation behavior of nicardipine was studied by HPLC 
under UV and daylight conditions and the main degradation product, 
identified as the pyridine analogue of the drug parent, was 
confirmed by mass spectrometry [58]. The two polymorph forms α-
and β-of nicardipine were studied by FTIR, X-ray diffraction analysis 
and differential scanning calorimetry to evaluate the photostability 
and other physicochemical properties. The solid form of the drug 
was also reported to be transformed into the pyridine derivative 
when exposed to light. The two crystalline forms changed to nearly 
amorphous form after irradiation grinding in a mixer mill. The 
Ragno et al. 
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apparent photodegradation rate constant of β-form was greater than 
that of α-form [59]. 
Nifedipine 
Nifedipine represents the lead of the DHP class and several papers 
have been published about its behavior under light. These studies 
have shown rapid photodegradation of the drug with the formation 
of two main photoproducts: the pyridine derivative from oxidation 
of the dihydropyridine ring and the nitroso derivative from the 
reduction of the nitro group. In the last years, degradation kinetics of 
nifedipine was studied by MCR, based on the combination of Kubista 
method and iterative target transformation method of Gemperline 
[60]. The spectra from degradation experiments were subjected to 
factor analysis revealing a photodecomposition kinetics of zero-
order with the formation of the nitroso-pyridine derivative as the 
major degradation product and the pyridine derivative in less 
content. The photodecomposition kinetics changed to a first-order 
when the nifedipine concentration reached a value of less than 50%. 
Photostability of nifedipine was quantitatively analyzed by a 
photocalorimeter adopting light emitting diode (LED) arrays. Five 
LEDs were used to create an array from 360 to 700 nm. The LEDs in 
this experiment operated individually in order to determine the 
wavelength responsible of the degradation, found to be 360 nm [61]. 
In a subsequent work, photodegradation experiments on nifedipine, 
monitored by DAD analysis, confirmed that the wavelengths 
responsible of degradation are in the spectral region 280–400 nm. 
The formation of the pyridine and nitroso photoproducts was 
confirmed too, obeying a unimolecular mechanism [8]. In this work, 
a new reaction order (the so-called Φ-order) was identified and 
proposed for unimolecular photodegradation reactions. The 
quantum yield of nifedipine was found to increase with irradiation 
wavelength and its photostability improved by increasing drug or 
excipients concentration. Stability studies on nifedipine in the solid 
state were monitored by 1H–14N NMR–NQR double resonance 
(NQDR). The nitroso-nifedipine by-product was detected upon long-
term daylight exposure. This photo-conversion was found to be 
accompanied with the electron density redistribution at the nitrogen 
sites [62]. 
Nilvadipine 
Photodegradation of nilvadipine under UV light was found to cause 
the aromatization of the dihydropyridine ring and elimination of the 
HCN molecule, leading to the formation of three photoproducts. The 
exposure of nilvadipine to UV light was found to lead to 
aromatization of the DHP ring and elimination of HCN [63]. The 
experiments were monitored by GC-MS. In another work, the 
photochemical decomposition in methanol solution was performed 
under a high-pressure mercury arc lamp (300-400 nm). The 
experiments were monitored by UV spectrophotometry and HPLC. 
The two methods allowed the calculation of the kinetic parameters 
of photodegradation from the relationship ln c = f(t). The results 
obtained by HPLC and UV techniques did not show significant 
difference [64]. 
Nimodipine 
A direct method for the simultaneous quantification of nimodipine 
and its pyridine derivative, as main photoproduct, was developed by 
using the derivative spectrophotometric technique. The results were 
compared with those obtained by gaschromatography [65]. The 
photochemical behavior of nimodipine was also studied in 
comparison with that of felodipine. Nimodipine resulted more 
photo-labile than felodipine, due to the presence of different 
substituents on the 4-phenyl moiety. The nitro group is probably 
responsible in the formation of the pyridine derivative as main 
photodegradation product [47].  
Nisoldipine 
Nisoldipine under daylight and UV light exposure gave the 4-(2-
nitrosophenyl) pyridine and pyridine photoproducts, under both 
irradiation conditions. The test was monitored by UV derivative 
spectrophotometry [66]. In contrast, another work about 
photodegradation of this drug in solid state reported the appearance 
of the nitroso-phenyl-pyridine photoproduct under daylight while 
the formation of nitro-phenyl-pyridine under UV light. 
The photodegradation kinetics of solid-state drug was considered to 
be zero-order reaction [67]. Separation of nisoldipine and 
photodegradation products was obtained by HPTLC on LiChrospher 
Si 60 F254s plates [68]. 
Nitrendipine 
Estimation of stability to light of nitrendipine was defined by HPLC, 
HPTLC and spectrophotometry, in both acidic and alkaline media. 
Photodegradation was found faster in acidic medium, following a 
first-order kinetics. The dehydro-nitrendipine was confirmed as the 
main degradation product [58]. These results were confirmed in 
another work in which nitrendipine and dehydro-nitrendipine were 
well resolved in the HPLC chromatogram [69, 70]. The simultaneous 
quantification of nitrendipine and photoproduct was proposed by 
using third-order derivative spectrophotometry and gas-
chromatography [71]. Photodegradation kinetics was also studied 
by self-modeling curve resolution method applied on the UV spectral 
data, combining iterative target transformation and Kubista method. 
This multivariate procedure allowed to estimate concentration 
profiles and pure spectra of the components involved in the 
photodegradation process [14]. 
Trombodipine 
Photostability and phototoxic potential of a new 4-alkyl-1,4-
dihydropyridine, namely trombodipine, were investigated by using a 
multilamp photoreactor centered at 350 nm. The drug exhibited a 
slow photodegradation, showing first-order kinetics that decreased in 
the absence of oxygen. Irradiation of red blood cells and Hep-2 (human 
larding carcinoma cell line) did not show phototoxic effects [72]. 
Photodegradation of dihydropyridines in biological samples 
Appropriate precautions for storage and handling of plasma samples 
containing DHPs should be adopted so to avoid the 
photodecomposition of the analytes. To investigate this topic, 
photostability of eleven DHPs was monitored in spiked plasma 
samples exposed to laboratory light. The screening procedure was 
performed by analyzing the samples by LC-MS-MS. Nifedipine and 
nisoldipine were reduced by 75% in just 2 h. In a manner similar to 
in vitro reactions, the pyridine analogue resulted as the main 
degradation product, referred also as the first metabolite in the 
metabolic pathway. Lercanidipine and nicardipine showed further 
ester hydrolysis after this first oxidation reaction. Several additional 
minor degradation products were found for the other drugs [73].  
With the aim to define the most adequate conditions for 
handling nifedipine solutions in the analytical laboratory, a micellar 
LC method was proposed to reduce the drug degradation in different 
biological matrices, such as serum and urine. This method was 
shown to increase the stability of nifedipine, thus 
preventing photodegradation and allowing the direct analysis of 
biological samples. This procedure did not show interferences or 
matrix effects produced by endogenous compounds [74]. 
Photosensitivity and photoxicity of dihydropyridines drugs 
It is known that some drugs that easily react to light can cause 
phototoxic skin responses even after systemic administration. The 
drug or its metabolites can act as chromophores and absorb energy 
from light, turning into an "excited" state with high energy content. 
When the molecules return to the fundamental state, the absorbed 
energy is transferred to neighboring tissues causing damage. Free 
radicals or toxic photoproducts that can damage DNA or cell 
membranes can be also formed. This problem has been deepened for 
DHP drugs in an interesting work of 2007 [47], where a series of 
drugs of this class were exposed to artificial light, showing a 
significant production of singlet oxygen, superoxide or both. The 
formation of these species indicated the potential photosensitivity 
that could lead to phototoxic dermatitis. In the same work, the 
photochemical behavior of felodipine and nimodipine was 
compared. Both compounds were able to generate singlet oxygen, 
however nimodipine was more photo-labile in excited 
state, while felodipine showed a major reactivity in its ground state. 
The results showed the difficulty in discriminating which specie is 
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responsible for the photoallergic and phototoxic effects, because 
these effects could be attributed to the participation of zwitterionic 
radicals in the photodegradation process and/or to ability in 
generating singlet oxygen. In another work, the photosensitizing 
properties of dihydropyridine drugs, with regard to bradykinin 
B2
Photostabilization approaches 
 receptor antagonist activity, were evaluated by monitoring the 
reactive oxygen species (ROS) generated from the compounds 
irradiated with UV light. The production of singlet oxygen and 
superoxide were confirmed, with a potential peroxidation of fatty 
acids that could lead to phototoxic dermatitis. The addition of radical 
scavengers, such as butylated hydroxyanisole, reduced glutathione 
and N-(2-mercaptopropionyl) glycine (MPG) and seemed to 
attenuate the lipid peroxidation, suggesting so the involvement of 
ROS in promoting the occurrence of phototoxic processes [75]. 
Because of instability to light, almost all DHP antihypertensive are 
marketed in solid pharmaceutical formulations. Several studies have 
been proposed or have been undertaken to define new formulations 
or to design other technological systems able of providing valid 
photoprotection for these drugs. At present, only few specialties are 
marketed in solution form, packaged in amber glass containers or 
other completely opaque materials. 
The photoprotective effect of a series of containers in different 
glassy or polymeric matrices was investigated with regard to four 
DHPs in solution, felodipine, lercanidipine, nimodipine, nifedipine 
[76]. The samples were submitted to stress test under Xenon lamp 
and the experiments were monitored by UV spectrophotometry. The 
spectral data were elaborated by MCR, able to estimate the kinetic 
parameters and resolve the spectra of the components involved in 
the photodegradation process. Polyethylene terephthalate (PET) 
containers proved to give a significant photoprotection for all drugs. 
The best result was reached for the felodipine solution in 
transparent blue PET, showing complete stabilization up to six hours 
under stressing irradiation. The amber glass containers did not 
provide analogous photoprotection. These results sound very 
interesting to design liquid dosage forms of DHPs as an alternative 
to the solid forms. Another approach increasing the photostability of 
the DHP specialties is the addition of light absorbing excipients, 
usually presenting absorption spectra similar to those of the drugs. 
Even the presence of antioxidants has gained good results. The 
influence of β-carotene on the photostability of nisoldipine was 
studied in stressing conditions, using a high-pressure mercury lamp 
as irradiation source. The photodegradation process was monitored 
by UV spectrophotometry and HPLC. The degradation rate constant 
of a methanol solution of nisoldipine decreased as β-carotene 
concentration increased, confirming the role of this excipient as 
photoprotective agent [77].  
Over the last few years, great interest aroused the supramolecular 
matrices, which are able to incorporate a high number of drugs 
through non-covalent bonds, even if they are difficult soluble in 
other systems. The most famous of these complex matrices are the 
"self-assembled" structures, of which the liposomes are the most 
representative, and the "host-guest systems", among which the most 
famous "hosts" are the cyclodextrins (CD) [78, 79]. A series of DHPs 
were incorporated in liposomes and CD and the ability of the 
resulting complexes in protecting from light was investigated. 
Optimal photoprotection of all the drugs was demonstrated for both 
the systems. Only manidipine and lercanidipine showed not 
satisfactory results, due to the low inclusion in the supramolecular 
matrices [80]. Inclusion complexes of felodipine in β-CD was 
obtained in a binary or ternary system with addition of polyethylene 
glycol 6000. Solubility of felodipine increased 10 fold in liquid three-
component complexes. The complexes were studied by IR 
spectroscopy, differential scanning calorimetry and 13C-NMR. 
Complexation of the drug with β-CD caused a two-fold increase of 
the photodegradation rate if compared with its crystalline form [81].  
Photostability of amlodipine was monitored after incorporation in 
CD, liposomes and microspheres. The photodegradation process was 
conducted according to the ICH Guideline and monitored by 
spectrophotometry. After a radiant exposure of 11,340kJm-2
Barnidipine photostability was investigated in CD or liposome 
matrices and in appropriate combinations of these matrices, as an 
alternative to the current solid specialties. The drug was subdued to 
photodegradation stressing tests and monitored by derivative 
spectrophotometry. The residual concentration of the drug in 
liposome and CD matrices was42.90 and 72.03%, respectively, after 
a radiation exposure of 225 kJm
, all the 
formulations were found to increase drug stability, with a residual 
drug concentration of 90 and 77% in CD and liposomes, respectively, 
and an excellent value of 97% in microspheres [82]. A dry oil-in-
water emulsion was prepared, using labrafil M1944CS and dextrin, 
to improve the photostability of amlodipine. This formulation 
greatly improved the photostability of the drug and at the same time 
increased its bioavailability. The photodegradation study proved 
that 94.4% of amlodipine remained intact after 24-h UV irradiation 
versus 33.1% as powder [83]. Photostability of felodipine in (2-
hydroxypropyl)-β-CD was studied in presence of water soluble 
polymers as polyvinylpyrrolidone, polyethylene glycol and 
hydroxypropyl-methylcellulose. Drug solubility resulted very 
improved and, at the same time, a dramatic decrease in degradation 
rate constants of the drug-in-CD complex was observed [84]. The 
photochemical behavior of nimodipine and felodipine was evaluated 
when incorporated in biological-mimicking systems like micelles or 
liposomes. The micelles were formed by using ionic or nonionic 
surfactants, as sodium dodecyl sulfate, dodecyl-pyridinium chloride 
and mono lauryl sucrose ester, in order to study the influence of the 
surface charge in modulating the photo-reactivity of these drugs. 
Both drugs were demonstrated to be located near to the interface 
but the photodegradation rate did not change with the surface 
charge [85]. 
-2. This value reached the value of 
90.78% when the drug-CD complex was in turn entrapped in 
liposomes, very close to that calculated in tablets (96.03%) [86]. 
Incorporation of isradipine in CD has been exposed in several 
papers. Isradipine is a highly hydrophobic drug and is practically 
insoluble in water. Incorporation in supramolecular matrices were 
aimed to both increase its solubility and photostability. Differential 
scanning calorimetry and X-ray diffraction were adopted to study 
the physicochemical properties of the inclusion complexes of 
isradipine in β-CD. The first aim of this work was to develop 
isradipine formulations able to increase the passage of the drug 
through the buccal membrane. Isradipine in these complexes 
resulted more stable than pure drug [87]. Isradipine was also chosen 
to prepare sustained release hydroxypropylmethyl-cellulose tablets 
containing inclusion complex of the drug in β-CD. The 
physicochemical properties of the complexes and solubility tests 
were measured by differential scanning calorimetry and FTIR. 
Photostability of the drug in the complex was more stable than pure 
isradipine up to four days radiation [88]. The process of 
photodegradation of isradipine incorporated in methyl-β-CD was 
also studied by UV spectrophotometry, HPLC and HPTLC. 
Photodegradation rate constant (k), half-life period (t0.5) and time of 
degradation of 10% (t0.1
The use of polymers for supramolecular matrices is a recent 
approach, but they are already experiencing a wide application 
success. Incorporation systems represented by polymer-based 
microspheres or microcapsules are widely studied in controlled 
release systems. Microspheres are spherical particles of micron size, 
typically prepared using natural or synthetic polymers. 
Microspheres allow continuous drug concentration with a 
corresponding decrease in single dose and a reduced frequency of 
) were calculated. Inclusion in CD increased 
twice the photostability of the drug [50]. Incorporation of 
nicardipine in CD was evaluated in terms of photostability in 
aqueous solution under exposure to UV(A)-UV(B) radiations. 
The photodegradation process was monitored by capillary 
electrophoresis using (2, 3, 6-tri-O-methyl)-β-CD as chiral selector, 
able to provide the enantio-resolution of the nicardipine 
enantiomers. Photostability was estimated for the inclusion 
complexes of the racemic nicardipine with α-CD, β-CD, γ-CD, 
hydroxypropyl-α-CD, hydroxypropyl-β-CD, hydroxypropyl-γ-CD, (2-
hydroxyethyl)-β-CD and methyl-β-CD. The matrices studied showed 
satisfactory photoprotective effect. In contrast, α-CD was found to 
favor drug photodegradation. Two distinct photo-degradation profiles, 
with relative kinetic constants (k), were observed for 
the nicardipine enantiomers only for the β-CD complex [89]. 
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administration. Polymeric nanocapsules containing nifedipine were 
prepared with the aim to preserve the drug from degradation. The 
surfactants pluronic F68 and polyvinyl alcohol were used to prepare 
the nanocapsule suspensions. The solid drug and the nanocapsules 
were submitted to light exposure. Particle size, zeta potential and 
entrapment efficiency remained constant during a period of 28 d 
under light exposure. The pure drug was completely degraded after 
4 d while the percentage of drug remaining in the nanocapsules was 
around 25-30%, suggesting a significant protection of the drug into 
this matrix [90]. Porous calcium silicate was evaluated for increasing 
the photostability of nifedipine in a solid dispersion formulation. 
This formulation was more stable to light irradiation than a classical 
formulation of the drug in microcrystalline cellulose. The 
photoprotection was hypothesized to be due to the physical 
shielding against light [91]. Another approach to improve the 
stability of nifedipine was proposed by complexation with weak 
cation-exchange resins, indion 204 and indion 264.  
The tablets were subdued to artificial light and indirect sunlight and 
the results compared with those from pure drug. Indion 204 was 
found to be a valid complexing agent for reducing the 
photosensitivity of nifedipine in tablets [92]. 
 
Table 2: Main studies about photodegradation and photostabilization of DHPs 
DHP Photodegradation studies Photostabilization studies 
Amlodipine Kawabe et al., 2008 [11]. 
Fasani et al., 2008 [30]. 
Ragno et al., 2002 [31]. 
Zhu et al., 2015 [32]. 
Jakimska et al., 2014 [33]. 
Stoiljkovic et al., 2014 [34]. 
Ragno et al., 2003 [83]. 
Jang et al., 2006 [84]. 
Aranidipine Ohashi and Ebihara, 1996 [35]. 
Kuwata et al., 1993 [36]. 
 
Azelnidipine Patel and Patel, 2014 [38].  
Barnidipine Ioele et al., 2010 [40]. 
Cheng et al., 2014 [42]. 
Ioele et al., 2014 [86]. 
Benidipine Karasaka, 2015 [43].  
Cilnidipine Kadam et al., 2015 [44].  
Clevidipine Zhou et al., 2015 [45].  
Felodipine Javidnia et al., 2008 [14]. 
Cardoza and Amin, 2002 [46]. 
Pizarro et al., 2007 [47]. 
De Luca et al., 2016 [76]. 
Mielcarek, 1998 [81]. 
Narkhede et al., 2011 [84]. 
Brito et al., 2012 [85]. 
Flordipine Narurkar et al., 1986 [48].  
Furnidipine Núñez-Vergara et al., 1994 [49].  
Isradipine Mielcarek and Daczkowska, 1999 [50]. Mielcarek and Daczkowska, 1999 [50]. 
Himabindu et al., 2013 [88]. 
Park et al., 2013 [89]. 
Lacidipine De Filippis et al., 2002 [10]. 
Belal et al., 2009 [51]. 
Dinç et al., 2012 [52]. 
Ragno et al., 2006 [53]. 
 
Lercanidipine Fiori et al., 2006 [54]. De Luca et al., 2016 [76]. 
Manidipine Ragno et al., 2003 [55]. 
Todeschini et al., 2015 [56]. 
 
Nicardipine Ragno and Vetuschi, 1998 [57]. 
Bonferoni et al., 1992 [58]. 
Teraoka et al., 2004 [59]. 
Pomponio et al., 2004 [89]. 
 
Nifedipine Maafi and Maafi, 2013 [8]. 
Shamsipur et al., 2003 [60]. 
Dhuna et al., 2008 [61]. 
Latosińska et al., 2012 [62]. 
Tagliari et al., 2015 [90]. 
Fujimoto et al., 2016 [91]. 
Shende and Markandeeywar, 2010 [92]. 
Nilvadipine Mielcarek et al., 2000 [63]. 
Augustyniak et al., 2001 [64]. 
 
Nimodipine Ragno et al., 1995 [65]. 
Pizarro et al., 2007 [47]. 
Brito et al., 2012 [85]. 
Nisoldipine Marinkovic et al., 2000 [66]. 
Marinkovic et al., 2003 [67]. 
Agbaba et al., 2004 [68]. 
Mielcarek et al., 2005 [77]. 
Nitrendipine Javidnia et al., 2008 [14]. 
Tipre and Vavia, 2001 [69]. 
Álvarez-Lueje et al., 2002 [70]. 
Ragno et al., 1993 [71]. 
 
Trombodipine Cortés et al., 1993 [72].  
 
Conclusions and future developments 
Drug photostability has become an emerging topic in pharmaceutical 
research after the discovery of a high number of light-sensitive 
drugs and the possibility of phototoxic effects. At present, the 
pharmaceutical industry is obliged to test the photostability of the 
new drugs by following appropriate international guidelines to 
verify any changes after exposure to light. Unfortunately, all 
antihypertensive drugs belonging to the DHP class, which are the 
most used drugs for antihypertensive therapy, have a particular light 
sensitivity, completely losing therapeutic activity when degraded. 
For this reason, many analytical techniques, especially 
chromatographic and spectrophotometric, have been proposed to 
monitor the stability of these drugs. Understanding the kinetics and 
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the reaction mechanism can be useful for the synthesis of novel 
photostable molecules or to define formulations that can minimize 
their photodegradation. 
The most modern studies seek to overcome the adoption of 
traditional dark or opaque containers with the use of excipients, able 
to absorb visible and UV wavelengths, or of supramolecular 
matrices. The matrices that have so far shown the best results are 
liposomes or niosomes and cyclodextrins. These systems are able of 
incorporating drugs of different solubility and magnitude. One of the 
major benefits that can be obtained from these studies will be the 
formulation of DHPs in solution, which is currently absent because 
of their high photodegradation rate in solution form. 
The increase in photostability of DHPs can also be pursued with 
targeted changes in their molecular structure. Some studies report 
condensed ring systems carrying 1,4-DHP structure, such as 
hexahydroquinolines, indenopyridines, acridines and furo-
quinolines. Also cyclopentane, cyclohexane or tetra-hydro-thiophene 
rings fused to the DHP ring seem influence both activity and 
photostability of such compounds. The electronic nature of 
substituents attached to the 4-aryl moiety of 1,4-dihydropyridines 
was demonstrated to strongly affect the photophysical and 
photochemical behavior of DHPs. The presence of an electron donor 
substituent on the 4-aryl moiety decreased the photodecomposition 
quantum yields. The same result was reached with the absence of 
electron-withdrawing substituents. In addition, the adoption of 
specific QSPR mathematical models, correlating the molecular 
substituents versus the photodegradation rate, may be of great 
utility to draw photostable molecules. 
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